Skip to main content

Angina

5
Pipeline Programs
6
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 18 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
7 programs
2
2
1
RanolazinePhase 41 trial
RanolazinePhase 31 trial
RanolazinePhase 31 trial
RanolazinePhase 21 trial
RanolazinePhase 21 trial
+2 more programs
Active Trials
NCT03134105Withdrawn0Est. Jul 2018
NCT02147834Terminated5Est. Sep 2016
NCT02265796Completed50Est. Sep 2016
+3 more trials
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
7 programs
Monthly Feedback on activity and patient-reported anginaN/A
RanolazinePHASE_2
RanolazinePHASE_3
RanolazinePHASE_3
RanolazinePHASE_3
+2 more programs
Abbott
AbbottABBOTT PARK, IL
2 programs
XIENCE PRIME - Long LengthN/A1 trial
XIENCE V / PROMUS stentN/A1 trial
Active Trials
NCT01721096Completed536Est. Nov 2018
NCT01086228Completed2,010Est. Aug 2016
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
RanolazineN/A1 trial
Active Trials
NCT01804543Unknown30Est. Dec 2014
TSH Biopharm
TSH BiopharmTaiwan - Taipei
1 program
RanolazineN/A1 trial
Active Trials
NCT03401502Completed20Est. Mar 2019
Sandoz
SandozAustria - Kundl
1 program
AtenololPHASE_1Small Molecule1 trial
Active Trials
NCT00946725Completed28Est. Nov 2000

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kite PharmaRanolazine
Kite PharmaRanolazine
Kite PharmaRanolazine
Kite PharmaRanolazine
Kite PharmaRanolazine
SandozAtenolol
TSH BiopharmRanolazine
Kite PharmaMonthly Feedback on activity and patient-reported angina
AbbottXIENCE PRIME - Long Length
Angeles TherapeuticsRanolazine
AbbottXIENCE V / PROMUS stent

Clinical Trials (11)

Total enrollment: 3,230 patients across 11 trials

NCT03044964Kite PharmaRanolazine

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

Start: Jan 2017Est. completion: Oct 201740 patients
Phase 4Unknown
NCT01174173Kite PharmaRanolazine

Ranolazine and Pulmonary Hypertension

Start: Jun 2010Est. completion: Oct 201411 patients
Phase 3Completed
NCT00091429Kite PharmaRanolazine

Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine

Start: Aug 2004Est. completion: Feb 2005500 patients
Phase 3Completed
NCT02147834Kite PharmaRanolazine

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

Start: Aug 2015Est. completion: Sep 20165 patients
Phase 2Terminated
NCT02265796Kite PharmaRanolazine

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

Start: Sep 2014Est. completion: Sep 201650 patients
Phase 2Completed
NCT00946725SandozAtenolol

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

Start: Nov 2000Est. completion: Nov 200028 patients
Phase 1Completed
NCT03401502TSH BiopharmRanolazine

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency

Start: Jun 2018Est. completion: Mar 201920 patients
N/ACompleted
NCT03134105Kite PharmaMonthly Feedback on activity and patient-reported angina

A Wearable EducAtional Intervention to REduce Angina

Start: Sep 2017Est. completion: Jul 20180
N/AWithdrawn
NCT01721096AbbottXIENCE PRIME - Long Length

XIENCE PRIME Japan Post-Marketing Surveillance (PMS)

Start: Oct 2012Est. completion: Nov 2018536 patients
N/ACompleted
NCT01804543Angeles TherapeuticsRanolazine

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

Start: Jun 2012Est. completion: Dec 201430 patients
N/AUnknown
NCT01086228AbbottXIENCE V / PROMUS stent

XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Start: Mar 2010Est. completion: Aug 20162,010 patients
N/ACompleted

Related Jobs

Clinical Research Scientist - VahatiCor

VahatiCorVahatiCor
Santa Clara, California, United States
1mo ago
$144K - $195K/yr

Product Development Manager - Advanced NanoTherapies (ANT)

VahatiCorVahatiCor
Cleveland, Ohio, United States
1mo ago
$115K - $136K/yr

Field Clinical Engineer - VahatiCor

VahatiCorVahatiCor
Santa Clara, California
2mo ago
$136K - $184K/yr

Manufacturing Operator - Advanced NanoTherapies

VahatiCorVahatiCor
Cleveland, Ohio
2mo ago
$20 - $25/hr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.